Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China

Ping Wu, MD; Fang Duan, MD; Chunhua Luo, MD; Qiang Liu, MD; Xingguang Qu, MD; Liang Liang, MD; Kaili Wu, MD

IMPACTANCE While the outbreak of coronavirus disease 2019 (COVID-19) has resulted in more than 100,000 infected individuals in China and worldwide, there are few reports on the association of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with ocular abnormalities. Understanding ocular manifestations of patients with COVID-19 by ophthalmologists and others may facilitate the diagnosis and prevention of transmission of the disease.

OBJECTIVE To investigate ocular manifestations and viral prevalence in the conjunctiva of patients with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS In this case series, patients with COVID-19 treated from February 9 to 15, 2020, at a hospital center in Hubei province, China, were retrospectively reviewed for ocular manifestations. During the period of treatment, the ocular signs and symptoms as well as results of blood tests and reverse transcriptase–polymerase chain reaction (RT-PCR) from nasopharyngeal and conjunctival swabs for SARS-CoV-2 were noted and analyzed.

MAIN OUTCOMES AND MEASURES Ocular signs and symptoms as well as results of blood tests and RT-PCR for SARS-CoV-2.

RESULTS Of the 38 included patients with clinically confirmed COVID-19, 25 (65.8%) were male, and the mean (SD) age was 65.8 (16.6) years. Among them, 28 patients (73.7%) had positive findings for COVID-19 on RT-PCR from nasopharyngeal swabs, and of these, 2 patients (5.2%) yielded positive findings for SARS-CoV-2 in their conjunctival as well as nasopharyngeal specimens. A total of 12 of 38 patients (31.6%; 95% CI, 17.5-48.7) had ocular manifestations consistent with conjunctivitis, including conjunctival hyperemia, chemosis, epiphora, or increased secretions. By univariate analysis, patients with ocular symptoms were more likely to have higher white blood cell and neutrophil counts and higher levels of procalcitonin, C-reactive protein, and lactate dehydrogenase than patients without ocular symptoms. In addition, 11 of 12 patients with ocular abnormalities (91.7%; 95% CI, 61.5-99.8) had positive results for SARS-CoV-2 on RT-PCR from nasopharyngeal swabs. Of these, 2 (16.7%) had positive results for SARS-CoV-2 on RT-PCR from both conjunctival and nasopharyngeal swabs.

CONCLUSIONS AND RELEVANCE In this study, one-third of patients with COVID-19 had ocular abnormalities, which frequently occurred in patients with more severe COVID-19. Although there is a low prevalence of SARS-CoV-2 in tears, it is possible to transmit via the eyes.
Since December 2019, coronavirus disease 2019 (COVID-19) has been reported among patients in China. Currently, the disease is quickly spreading worldwide. The pathogen of COVID-19 is a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), identified as a member of the Coronaviridae family. Another coronavirus, named SARS-CoV-1, was responsible for severe acute respiratory syndrome.\(^1\) Compared with SARS-CoV-1, SARS-CoV-2 has a similar binding receptor and similar pathologic features systemically and epidemiologically.\(^1,2\) Although there is no direct evidence that SARS-CoV-1 replication results in conjunctivitis and other ocular diseases, reports have emphasized the eye as a potential site for virus transmission.\(^3\) Similarly, SARS-CoV-2 transmission through the eye has been suspected.

Nevertheless, there are no reports in the medical literature at this time, to our knowledge, that identify a direct relationship between SARS-CoV-2 and the eye. Researchers have not reported ocular abnormalities nor have they stated in the medical literature if there was conjunctivitis or viral presence detected in the tears of patients with COVID-19. The objective of this study was to evaluate ocular involvement systematically in patients highly suspected of having or confirmed to have COVID-19.

Methods

From February 9 to 15, 2020, patients with COVID-19 hospitalized in Yichang Central People’s Hospital were diagnosed based on the 5th edition of the National Guideline on Prevention and Control of the Novel Coronavirus Pneumonia (PC-NCP) published by the National Health Commission of China on February 8, 2020.\(^4\) The patient symptoms, ocular manifestations, chest computed tomographic scans, and results of blood tests and reverse transcriptase–polymerase chain reaction (RT-PCR) from nasopharyngeal and conjunctival swabs for SARS-CoV-2 were noted and analyzed. This study was approved by the ethics committee of Yichang Central People’s Hospital, and all patients gave written informed consent. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc). Means for continuous variables were compared using independent-group t test when the data were normally distributed; otherwise, the Mann-Whitney test was used. Proportions for categorical variables were compared using the \(\chi^2\) and Fisher exact test as appropriate. For unadjusted comparisons, a 2-sided \(p\) of less than .05 was considered statistically significant.

Results

Of the 38 consecutive patients with COVID-19 who were recruited, 25 (65.8%) were male, and the mean (SD) age was 65.8 (16.6) years (Table 1). Among them, 28 patients (73.7%) had positive findings for COVID-19 on RT-PCR from nasopharyngeal swabs, and of these, 2 patients (5.2%) yielded positive findings for SARS-CoV-2 in their conjunctival as well as nasopharyngeal specimens. The other 10 patients who were hospitalized were judged to have COVID-19 by the guideline of PC-NCP,\(^4\) with fever and/or respiratory symptoms and lung computed tomography imaging features of COVID-19 pneumonia.

A total of 12 of 38 patients (31.6%; 95% CI, 17.5-48.7) had ocular manifestations consistent with conjunctivitis, including conjunctival hyperemia, chemosis, epiphora, and increased secretions (Table 2). Among these 12 patients, there were 4 cases judged as moderate, 2 cases judged as severe, and 6 cases judged as critical, which was graded according to the guideline of PC-NCP: moderate indicated fever and/or respiratory symptoms and lung computed tomography imaging findings; severe indicated dyspnea (respiratory frequency of 30 cycles per minute or greater), blood oxygen saturation of 93% or less, and an arterial partial pressure of oxygen to fraction of oxygen inspiration ratio of 300 or less; and critical indicated respiratory failure or shock or multiple organ dysfunction/failure.\(^4\) In these patients, 1 patient experienced epiphora as the first symptom of COVID-19. None of them experienced blurred vision. By univariate analysis, patients with ocular symptoms were more likely to have higher white blood cell and neutrophil counts and higher levels of procalcitonin, C-reactive protein, and lactate dehydrogenase than patients without ocular symptoms (Table 1). In addition, 11 of 12 patients with ocular abnormalities (91.7%; 95% CI, 61.5-99.8) had positive results for SARS-CoV-2 on RT-PCR from nasopharyngeal swabs. Of these, 2 (16.7%) had positive results for SARS-CoV-2 on RT-PCR from both conjunctival and nasopharyngeal swabs.

Discussion

Few previous investigations have evaluated ocular signs and symptoms in patients infected with SARS-CoV-1 and SARS-CoV-2. A few reports have evaluated for the presence of SARS-CoV-2 in tear fluid.\(^3,5\) Our investigation suggests that among patients with COVID-19, 31.6% (95% CI, 17.5-48.7) have ocular abnormalities, with most among patients with more severe systemic manifestations or abnormal findings on blood
Abbreviations: F, female; M, male; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Previous reports have shown the shedding of potentially infectious virus can occur in people who have no fever and minor or absent signs of infection. Because unprotected eyes were associated with an increased risk of transmission of SARS-CoV-2, our results might suggest that SARS-CoV-2 might be transmitted through the eye. Limitations of this study include a relatively small sample size and absence of detailed ocular examinations to exclude intraocular disease owing to the logistical challenges of tests. These results suggest that ocular symptoms commonly appear in patients with severe pneumonia.

Our results show a low prevalence (5.2%; 95% CI, 0.6-17.8) of SARS-CoV-2 nucleotides in conjunctival specimens of patients with COVID-19, consistent with previous studies on severe acute respiratory syndrome.3 Of note, we found only 1 patient presenting with conjunctivitis as the first symptom. Previous reports have shown the shedding of potentially infectious virus can occur in people who have no fever and minor or absent signs of infection. Because unprotected eyes were associated with an increased risk of transmission of SARS-CoV-2, our results might suggest that SARS-CoV-2 might be transmitted through the eye. Limitations of this study include a relatively small sample size and absence of detailed ocular examinations to exclude intraocular disease owing to the logistical challenges of

### Table 1. Clinical Laboratory Results of Patients With Coronavirus Disease 2019 (COVID-19)

| Measure                          | Mean (SD)                  | Ocular symptoms   | Total (N = 38) | Yes (n = 12) | No (n = 26) | Difference (95% CI) | P value |
|----------------------------------|----------------------------|-------------------|----------------|--------------|-------------|--------------------|---------|
| Age, median (IQR), y            | 68 (53 to 76)              | 67 (52 to 76)     | 70 (62 to 79) | −3.39 (−8.47 to 15.25) | .28        |
| Male, No. (%)                   | 25 (65.8)                  | 7 (58.3)          | 18 (69.2)     | −0.11 (−0.44 to 0.22) | .51        |
| Severe type, No. (%)            | 15 (39.4)                  | 8 (66.7)          | 7 (26.9)      | 0.40 (0.08 to 0.71) | .33        |
| White blood cell count, /μL     | 7360 (4480)                | 10 900 (5580)     | 5730 (2690)   | 5160 (2460 to 7860) | .009       |
| Lymphocyte count, /μL           | 890 (500)                  | 710 (480)         | 980 (490)     | −270 (−610 to 70) | .12        |
| White blood cell count to lymphocyte count ratio | 14.96 (20.23) | 26.20 (25.36) | 9.77 (15.30) | 16.43 (3.02 to 29.85) | .06 |
| Neutrophil count, /μL           | 5920 (4640)                | 9510 (5820)       | 4260 (2820)   | 5250 (2430 to 8070) | .01 |
| Monocyte count, /μL             | 500 (210)                  | 620 (280)         | 440 (150)     | 170 (30 to 3100) | .06       |
| Platelet count, ×10^3 /μL       | 184.39 (77.28)             | 184.58 (89.70)    | 184.31 (72.80)| 0.28 (−55.18 to 55.73) | .99       |
| PCT ≥0.05 ng/mL, No. (%)        | 15 (40.5)                  | 8 (66.7)          | 7 (28.0)      | 0.39 (0.06 to 0.71) | .03       |
| CRP, mg/dL                      | 5.17 (6.30)                | 8.55 (8.87)       | 3.61 (4.02)   | 4.95 (0.7 to 9.15) | .04       |
| D-dimer, μg/mL                  | 1.76 (2.42)                | 2.96 (3.93)       | 1.35 (1.53)   | 1.62 (−0.35 to 3.59) | .15       |
| Creatinine, mg/dL               | 101.82 (85.81)             | 91.08 (58.35)     | 106.77 (96.53)| −15.69 (−77.03 to 45.66) | .61 |
| Creatine kinase–MB, ng/mL       | 11.87 (5.67)               | 12.42 (4.94)      | 11.62 (6.05)  | 0.80 (−3.26 to 4.86) | .35       |
| LDH, U/L                        | 281.11 (154.47)            | 381.17 (196.52)   | 234.65 (105.89) | 147.10 (48.04 to 246.15) | .03       |
| Alanine aminotransferase, U/L   | 31.08 (27.46)              | 39.83 (45.25)     | 27.04 (12.69) | 12.79 (−6.43 to 32.02) | .36       |
| Aspartate aminotransferase, U/L | 35.58 (26.58)              | 45.33 (41.73)     | 31.08 (14.58) | 14.26 (−4.20 to 32.71) | .27       |
| Urea nitrogen, mg/dL            | 41.24 (128.83)             | 20.21 (15.37)     | 50.94 (155.41) | −30.72 (−122.58 to 61.14) | .50       |
| Creatinine, mg/dL               | 1.61 (2.84)                | 1.94 (3.81)       | 1.46 (2.34)   | 0.48 (−1.55 to 2.52) | .63       |

### Table 2. Characteristics of 12 Patients With Ocular Manifestations

| Patient No./ Sex/ Age, y | Temperature at ocular examination, °C | Respiratory symptoms | Clinical typea | Ocular manifestations | SARS-CoV-2 RNA test result | Nasopharyngeal swab | Conjunctival swab |
|--------------------------|--------------------------------------|----------------------|----------------|-----------------------|----------------------------|---------------------|-------------------|
| 1/F/80s                  | 38.0                                 | Dyspnea              | Severe         | Chemosis, epiphora    | Positive                   | Negative            |                  |
| 2/M/70s                  | 38.0                                 | Cough, expectorate   | Critical       | Secretion             | Positive                   | Negative            |                  |
| 3/M/50s                  | 39.9                                 | Cough, expectorate   | Critical       | Conjunctival hyperemia, secretion | Positive                   | Positive            |                  |
| 4/F/80s                  | 39.0                                 | Dyspnea              | Severe         | Conjunctival hyperemia, chemosis, epiphora, secretion | Positive                   | Negative            |                  |
| 5/F/60s                  | 36.8                                 | Cough                | Critical       | Chemosis, epiphora    | Positive                   | Positive            |                  |
| 6/M/60s                  | 38.7                                 | Cough, expectorate   | Critical       | Chemosis, epiphora, secretion | Positive                   | Negative            |                  |
| 7/F/80s                  | 36.5                                 | None                 | Moderate       | Chemosis, epiphora, secretion | Positive                   | Negative            |                  |
| 8/F/70s                  | 38.0                                 | Cough                | Critical       | Chemosis, epiphora    | Positive                   | Negative            |                  |
| 9/M/60s                  | 38.1                                 | None                 | Critical       | Chemosis, secretion   | Positive                   | Negative            |                  |
| 10/M/30s                 | 39.6                                 | Chest tightness      | Moderate       | Chemosis              | Positive                   | Negative            |                  |
| 11/M/40s                 | 37.1                                 | Cough                | Moderate       | Conjunctival hyperemia | Negative                   |                    |                  |
| 12/M/70s                 | 36.9                                 | None                 | Moderate       | Epiphora              | Positive                   | Negative            |                  |

Abbreviations: F, female; M, male; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

a Graded by the National Guideline on Prevention and Control of the Novel Coronavirus Pneumonia.4
Managing these patients at this time. In addition, we only sampled once from the eye of each patient, which can decrease the prevalence owing to false-negatives. Regardless, these preliminary results are shared in an effort to inform ophthalmologists and others around the world regarding ocular symptoms with COVID-19.

**ARTICLE INFORMATION**

Accepted for Publication: March 17, 2020.
Published Online: March 31, 2020. doi:10.1001/jamaophthalmol.2020.1291

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Wu P et al. JAMA Ophthalmology.

Author Contributions: Drs Liang and K. Wu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs P. Wu and Duan contributed equally to this study. Drs Luo, Liu, and Qu contributed equally as senior authors. Study concept and design: Liang, K. Wu. Acquisition, analysis, or interpretation of data: P. Wu, Duan, Luo, Liu, Qu, Liang. Drafting of the manuscript: P. Wu, Duan, Liang. Critical revision of the manuscript for important intellectual content: P. Wu, Luo, Liu, Qu, Liang, K. Wu. Statistical analysis: P. Wu. Obtained funding: Liang, K. Wu. Administrative, technical, or material support: Duan, Luo, Liu, Qu, Liang. Study supervision: Liu, Liang, K. Wu.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by grants 81770896 (Dr K. Wu) and 81770920 (Dr Liang) from the National Natural Science Foundation of China.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Haijiang Zhang, MD, Minxing Wu, MD, and Min Liu, MD (Yichang Central People’s Hospital, Yichang, China), for collecting the data and preparing the Table. None of these individuals received compensation for their contributions.

**REFERENCES**

1. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8

2. To KF, Lo AW. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol. 2004;203(3):740-743. doi:10.1002/path.1597

3. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349(25):2431-2441. doi:10.1056/NEJMo032498

4. National Health Commission of the People’s Republic of China. The guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP): revised version of the 5th edition. Accessed February 8, 2020. http://www.nhc.gov.cn/xcs/zhengcexinwen/202002/d4bf9537e19445f8d728fcafe3e31a.shtml

5. Loon SC, Teoh SC, Oon LL, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88(7):861-863. doi:10.1136/bjo.2003.035931

6. Hoehl S, Berger A, Kortenbusch M, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. Published online February 18, 2020. doi:10.1056/NEJMoa2001899

7. Raboud J, Shigayeva A, McGeer A, et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One. 2010;5(5):e10717. doi:10.1371/journal.pone.0010717

**Invited Commentary**

Humans, Viruses, and the Eye—An Early Report From the COVID-19 Front Line

Alfred Sommer, MD, MHS

**Viruses** have always been part of the human experience, most often in a delicate balance, otherwise the virus and its human host would become extinct. But this relationship is not particularly stable. Like all living substances, viruses mutate, sometimes in ways that cause explosive, severe disease. Viral outbreaks have killed off virtually entire populations, as happened when measles was first introduced into the previously naive population of the Faroe Islands, or when Europeans brought smallpox to North America. Human-kind, as a whole, has survived evolving viral threats by evolving with them; prior exposure to related viruses produces varying degrees of resistance (immunity) to new strains. Humans with less resistance die, often despite modern medical intervention, while others remain entirely asymptomatic. Medical interventions (principally vaccines) and stringent public health measures have often altered the outcome, but not necessarily in predictable ways.

The last “great” pandemic was the 1918 influenza pandemic that killed an estimated 20 to 50 million people worldwide. Its spread was enhanced by troop movements during World War I. The young, perhaps because of their more vigorous immune response, were disproportionately affected, dying from exuberant pulmonary exudation.1

As I compose this article, in mid-March 2020, the World Health Organization has just proclaimed the latest outbreak, termed novel coronavirus 19 (COVID-19), a global pandemic, the president of the United Sates has declared a national emergency, and all of Italy is locked down to contain its spread. Its future course and duration remain unknown. Estimates of case fatality range from 1% to 5% (10–50 times the mortality rate of seasonal influenza, although the real rate will only be known once we conduct serosurveys to determine the frequency of asymptomatic infections) and the elderly are at the greatest risk of severe disease and death. Modern air travel facilitated global dissemination within a very few months of its origins in Hubei province, China. This issue of JAMA Ophthalmology brings us necessarily preliminary but valuable insights from the front line.2 Wu et al2 examined the conjunctiva of 38 patients hospitalized in Hubei province, China, with presumed COVID-19. Conjunctivitis was present in 12 (32%) and it was most evident and severe in the sickest patients. The virus was